GGrantIndex
Sort

10,766 grants matching checkpoint inhibitor

SPORE: Targeted Therapies for Glioma

$2,438,174
Tracy T Batchelor · Brigham And Women'S Hospital · P50 · FY2019 · CA

The Memorial Sloan Kettering Cancer Center SPORE in Pancreas Cancer

$2,434,565
Eileen Mary O'Reilly · Sloan-Kettering Inst Can Research · P50 · FY2025 · CA

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 in a Community Oncology Setting

$2,425,687
Song Yao · Roswell Park Cancer Institute Corp · UH3 · FY2025 · CA

Genetics and Biology of Pancreatic Ductal Adenocarcinoma

$2,421,788
Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · P01 · FY2021 · CA

Epigenetic Therapies - New Approaches

$2,421,039
Jean-Pierre J Issa · Coriell Institute For Medical Research · P50 · FY2024 · CA

Lymphoma Specialized Program of Research Excellence (SPORE) in Human Cancer

$2,420,487
George J Weiner · University Of Iowa · P50 · FY2020 · CA

THE THERAPY OF AML

$2,404,845
Michael W Andreeff · University Of Tx Md Anderson Can Ctr · P01 · FY2007 · CA

Epithelial-Mesenchymal Interactions in Pulmonary Fibrosis and Chronic Allograft Dysfunction (CLAD)

$2,403,307
Paul Wesley Noble · Cedars-Sinai Medical Center · P01 · FY2018 · HL

THE THERAPY OF AML

$2,401,083
Michael W Andreeff · University Of Tx Md Anderson Can Ctr · P01 · FY2011 · CA

Liver Cancer Program

$2,400,798
Anuradha Budhu · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA

Computational studies of cancer immunotherapy

$2,397,559
Eytan Ruppin · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

Identifying small molecules with therapeutic effects in RELAFus -driven EPN, mand testing them in preclinical genetically engineered models of EPN

$2,394,581
Kevan M. Shokat · Fred Hutchinson Cancer Research Center · U54 · FY2019 · CA

Immunological Analysis of Brain Cancer

$2,394,103
Masaki Terabe · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA

Human Immune Responses to Tumor Antigens for Cancer Immunotherapy

$2,387,152
Jeffrey Schlom · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA

Genetics and Biology of Pancreatic Ductal Adenocarcinoma

$2,385,495
Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · P01 · FY2025 · CA

Dana Farber/Harvard Cancer Center SPORE in Lung Cancer

$2,384,337
David A Barbie · Dana-Farber Cancer Inst · P50 · FY2022 · CA

Dana-Farber/Harvard Cancer Center SPORE in Breast Cancer

$2,382,404
Eric P Winer · Dana-Farber Cancer Inst · P50 · FY2020 · CA

Genetics and Biology of Pancreatic Ductal Adenocarcinoma

$2,375,289
Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr · P01 · FY2023 · CA

Lymphoma Specialized Program of Research Excellence (SPORE) in Human Cancer

$2,375,000
George J Weiner · University Of Iowa · P50 · FY2017 · CA

SPORE in Gastrointestinal Cancers

$2,375,000
Alison P Klein · Johns Hopkins University · P50 · FY2020 · CA

THE THERAPY OF AML

$2,374,635
Michael W Andreeff · University Of Tx Md Anderson Can Ctr · P01 · FY2008 · CA

Leveraging Observational (Real World) Data to Advance Precision Oncology

$2,372,456
Charles L Sawyers · Sloan-Kettering Inst Can Research · P01 · FY2024 · CA

Yale SPORE in Skin Cancer

$2,369,171
Marcus W Bosenberg · Yale University · P50 · FY2020 · CA

Adeno-associated Virus Biology And Utilization For Gene Transfer

$2,369,091
Jay Chiorini · National Institute Of Dental & Craniofacial Research · ZIA · FY2019 · DE

Epithelial-Mesenchymal Interactions in Pulmonary Fibrosis and Chronic Allograft Dysfunction (CLAD)

$2,368,307
Paul Wesley Noble · Cedars-Sinai Medical Center · P01 · FY2019 · HL